Press Releases for BMY

Press Releases
AMRI Announces Fourth Quarter 2009 Results
Bristol-Myers-Squibb trade secrets stolen
Safety risk associated with HIV drug
MWB Consulting Joins SAFE-BioPharma Association
Mead Johnson Reports Solid Full-Year Results; Forecasts Stronger Sales Growth in 2010; Provides Initial EPS Guidance
Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009
Accelerate National Internet Exchange of Health and Patient Medical Information Using Existing Approaches, Expert Advises
Oxford Outcomes Joins SAFE-BioPharma Association
Mead Johnson Split-Off Successfully Completed
Bristol-Myers Squibb Updates 2009 Continuing Operations Financial Guidance
Bristol-Myers Squibb and Mead Johnson Announce Final Results of the Exchange Offer
Mead Johnson Board Declares Quarterly Dividend
Bristol-Myers Squibb and Mead Johnson Announce Preliminary Results of the Exchange Offer
Santa's Identity Verified via Digital Identity-Focused Holiday Greeting From SAFE-BioPharma
Rothman Research Issues Fundamental Research on Players in the Financial, Healthcare & Services Sectors
PicksThatMove.com Announces Investment Opinion on Bristol-Myers Squibb Co., Incyte Corp., EnCana Corporation, B2Gold Corp. and Medclean Technologies Inc.
Bristol-Myers Squibb Announces Split-Off of Mead Johnson
AMRI Announces Third Quarter 2009 Results
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
Mead Johnson Reports Solid Third Quarter Results; Narrows Full-Year 2009 Guidance to Top End of Range
Bristol-Myers Squibb Announces Dividend
Bristol-Myers Squibb Completes Acquisition of Medarex, Inc.
Bristol-Myers Squibb Completes Initial Tender Offer for Medarex, Inc. With 87.7% of Shares Tendered; Announces Subsequent Offering Period
Bristol-Myers Squibb Extends Tender Offer for Medarex, Inc.
Morning Watch for Wednesday: Sunwin International Neutraceuticals - August 19, 2009
StockPreacher.com issues Trading Outlook for Spectrum Pharmaceuticals Inc.
AMRI Announces Second Quarter 2009 Results
ZymoGenetics Reports Second Quarter 2009 Financial Results
UPI NewsTrack Business
Onglyza approved for Type 2 Diabetes
U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults
Medarex Announces 2009 Second Quarter Financial Results
Breaking News: SUWN - July 30, 2009
Bristol-Myers Squibb Begins Tender Offer to Acquire Medarex, Inc.
Excellent Performance Highlights Second Quarter for Bristol-Myers Squibb
Bristol-Myers Squibb to Acquire Medarex
ParagonReport.Com Complimentary Market Update on MRK, BMY, PFE and GSK
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Bristol-Myers Squibb’s SECURE THE FUTURE Announces $1.3 Million in New Grants to Enhance Community-Based HIV/AIDS Care and Support in Africa
Bristol-Myers Squibb to Announce Results for the Second Quarter and First Six Months of 2009 on July 23
New Online Resource Launches For Patients With Chronic Myeloid Leukemia
ONGLYZA™ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes
2009 Midyear New-Build Update: Pharmaceutical-Biotech Industry Completes Construction of 40 North American Facilities
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
Microsoft Announces Winners of the 2009 Pharmaceutical and Life Sciences Innovation Awards
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
Bristol-Myers Squibb Announces Dividend
Bristol-Myers Squibb to Present at Goldman Sachs Global Healthcare Conference
Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions
Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines
Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)
First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress
FDA Grants Full Approval for SPRYCEL® (dasatinib) for the Treatment of Adults with Chronic Myeloid Leukemia Who Are Resistant or Intolerant to Prior Therapies Including Gleevec®*
Bristol-Myers Squibb to Present at Bernstein Strategic Decisions Conference
Bristol-Myers Squibb Welcomes “Help is Here Express” to New Brunswick
Bristol-Myers Squibb to Present at Deutsche Bank Healthcare Conference
SPRYCEL® (Dasatinib) Shows Potential as Treatment for Prostate Cancer
Bristol-Myers Squibb to Present at Bank of America and Merrill Lynch Health Care Conference
AMRI Announces First Quarter 2009 Results
White Paper Examines the Importance of On-Dose Technologies in the Fight Against Illegal Diversion of Opioid Medications
Facet Biotech Reports First Quarter 2009 Financial Results
Bristol-Myers Squibb to Present at Bernstein Pharmaceutical Emerging Markets Conference
Bristol-Myers Squibb Invites Public to Listen to Webcast of 2009 Annual Meeting
Bristol-Myers Squibb Reports Excellent First Quarter Financial Results; Delivers on Two Significant Strategic Initiatives
Mead Johnson Reports Strong Sales Growth in Asia and Latin America for First Quarter of 2009; Initial 2009 Guidance Anticipates Record Year
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C
Institutional Investor Announces America's Best Investor Relations
Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Cosan Ltd., Petrobras, Bristol-Myers Squibb Co. And HSBC Holdings Plc
Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration With Otsuka
Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with Otsuka
Zacks Industry Outlook Highlights: Bristol-Myers, Johnson &Amp; Johnson and Abbott Labs
ONGLYZA™ (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee
Plavix(®) Plus Aspirin More Effective Than Aspirin Alone in Preventing Major Vascular Events in Patients with Atrial Fibrillation Who Cannot Take Oral Anticoagulants
Beacon Equity Issues Trade Alerts on Market Movers: ATW, GNK, SLE, BMY, BRCM, NCR
Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naïve Type 2 Diabetes Patients
Bristol-Myers Squibb Renews Contract WithCegedimDendrite
Together Rx Access(R) Program Expands Eligibility Criteria, Responds to Challenging Economic Times
Wall Street News Alert Reports Wednesday's Stocks to Watch: OCOL! March 18, 2009
Bristol-Myers Squibb to Present at Healthcare Conference - Mar 16 2009 4:01PM
Bristol-Myers Squibb to Present at Healthcare Conference - Mar 9 2009 4:58PM
Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation Compound
Bristol-Myers Squibb Announces Organizational Changes; Names Four to Company’s Executive Committee
Bristol-Myers Squibb Names Andreotti President and Chief Operating Officer
ZymoGenetics Collaboration With Bristol-Myers Squibb Clears Review Under Hart-Scott-Rodino Antitrust Improvements Act - Mar 2 2009 11:51PM
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX® in U.S.
Zacks Analyst Blog Highlights: Schering-Plough, Pfizer, Bristol-Myers, Citigroup and Credit Suisse Group
Zacks Bull and Bear of the Day Highlights: Onyx Pharma, Navigant Consulting, Bristol Myers, Biogen Idec and Strayer Education
Zacks Analyst Blog Highlights: ZymoGenetics, Bristol-Myers Squibb, Linear Technology, BioScrip Inc. And Marriott International Inc.
Bristol-Myers Squibb Foundation Announces Funding of More Than $1.17 Million to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in China, India and Taiwan
Bristol-Myers Squibb Statement on Mead Johnson Nutrition Company IPO
Zacks Analyst Blog Highlights: Eli Lilly & Co., Bristol-Myers, Sanofi-Aventis, Wells Fargo and Morgan Stanley
BenchmarkJournal.Com (Complimentary) Analyst Review for BMY, SNY, RTN and WYN
Zacks Bull & Bear of the Day Highlights: InterDigital, Overstock.Com, Sanofi-Aventis, Bristol-Myers Squibb and Biogen Idec
Zacks Analyst Blog Highlights: ZymoGenetics, Inc., Bristol-Myers Squibb, Tractor Supply Co., Interstate Hotels & Resorts, Inc. And Churchill Downs.
Zacks Analyst Blog Highlights: United States Steel Corporation, Iconix Brand Group, Bristol-Myers Squibb, Pfizer Inc. And Wyeth
Strong Fourth Quarter Supports Excellent 2008 for Bristol-Myers Squibb
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX®
Bristol-Myers Squibb To Announce Results For The Fourth Quarter And Full Year Of 2008 On January 27
Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound
Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience